For instance, the WHO estimates that the percentage of adults 60 or older was 9.8% in 2017 and will rise to 13.7% and 20.3%, respectively, in 2030 and 2050. Similarly, the U.S. general population's fastest-growing demographic is currently seniors (aged 65 and over).
Furthermore, the market for advanced wound care is anticipated to be significantly impacted by technological developments in advanced wound care products. It is anticipated that some of the most cutting-edge technological goods in this area will soon enter the market. For instance, bioactive molecules across the treated area, which maintain the drug release and specifically enhance the therapeutic effects of pharmaceuticals, are used in nanoparticle-based wound healing and skin regeneration. Similarly, it is anticipated that gene therapy, which promotes wound healing by infusing healthy normal genes into cells, will start selling. The market for advanced wound care is thus anticipated to grow throughout the projected period because of such developments in advanced wound care products.
Increasing Prevalence of Diabetes globally
For instance, according to ScienceDirect, 20% of individuals who have diabetic foot ulcers may require amputation of the foot. Diabetic foot ulcers may impact more than 25% of the diabetic population
The rise in Chronic Diseases Prevalence
In the US, four out of ten people have two or more chronic diseases, making up six out of ten adults. The number of Americans with chronic diseases will rise by 46 million, or 37 percent, between 2000 and 2030.
Market Segmentation
The Global Advanced Wound Care Market is segmented based on
Recent Developments
The launch of ConvaMax, a superabsorber dressing for highly exuding wounds such pressure ulcers, leg ulcers, and diabetic foot ulcers was launched, in an announcement by ConvaTec in January 2020.
Integra LifeSciences announced a successful clinical outcome for Integra Bilayer Wound Matrix in May 2020. (IBWM). The company's portfolio of regenerative technologies includes this product, which makes use of collagen and amniotic fluid.
Market players
Abbott Nutrition, Boston Scientific Corporation, Amsino International Inc., ConMed Corporation, Cardinal Health Inc., C.R.Bard, Danone, Cook Medical, B. Braun Melsungen AG, Fresenius SE & Co. KGaA.
Attribute | Details |
Base Year | 2022 |
Historic Data | 2018 – 2021 |
Estimated Year | 2023 |
Forecast Period | 2024 – 2028 |
Quantitative Units | Revenue in USD Million, and CAGR for 2018-2022 and 2023-2028 |
Report coverage | Revenue forecast, company share, competitive landscape, growth factors, and trends |
Segments covered | Product Wound Type End-Use |
Regional scope | North America; Asia Pacific; Europe & CIS; South America; Middle East & Africa |
Country scope | United States; Canada; Mexico; China; India; Japan; Australia; South Korea; Germany; France; United Kingdom; Spain; Italy; Brazil; Argentina; Colombia; South Africa; UAE, Saudi Arabia; Turkey; Egypt. |
Key companies profiled | Abbott Nutrition, Boston Scientific Corporation, Amsino International Inc., ConMed Corporation, Cardinal Health Inc., C.R.Bard, Danone, Cook Medical, B. Braun Melsungen AG, Fresenius SE & Co. KGaA. |
Customization scope | 10% free report customization with purchase. Addition or alteration to country, regional & segment scope. |
Pricing and purchase options | Avail customized purchase options to meet your exact research needs. Explore purchase options |
Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |